Evoke Pharma, a biotech focused on the development of drugs to treat gastrointestinal disorders and diseases, announced terms for its IPO on Friday. The San Diego, CA-based company plans to raise $27 million by offering 2.1 million shares at a price range of $12 to $14. At the midpoint of the proposed range, Evoke Pharma would command a market value of $75 million.
Evoke Pharma, which was founded in 2007, plans to list on the NASDAQ under the symbol EVOK. Evoke Pharma initially filed confidentially on April 19, 2013. Aegis Capital is the sole bookrunner on the deal.
